Search

Your search keyword '"Phillips, Wayne A."' showing total 836 results
Start Over Author "Phillips, Wayne A."
836 results on '"Phillips, Wayne A."'

4. PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate

Author

Chessa, Tamara A.M., Jung, Piotr, Anwar, Arqum, Suire, Sabine, Anderson, Karen E., Barneda, David, Kielkowska, Anna, Sadiq, Barzan A., Lai, Ieng Wai, Felisbino, Sergio, Turnham, Daniel J., Pearson, Helen B., Phillips, Wayne A., Sasaki, Junko, Sasaki, Takehiko, Oxley, David, Spensberger, Dominik, Segonds-Pichon, Anne, Wilson, Michael, Walker, Simon, Okkenhaug, Hanneke, Cosulich, Sabina, Hawkins, Phillip T., and Stephens, Len R.

Published
2023
Full Text
View/download PDF

5. Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression

Author

Luk, Ian Y., Jenkins, Laura J., Schoffer, Kael L., Ng, Irvin, Tse, Janson W. T., Mouradov, Dmitri, Kaczmarczyk, Stanislaw, Nightingale, Rebecca, Burrows, Allan D., Anderson, Robin L., Arango, Diego, Dopeso, Higinio, Croft, Larry, Richardson, Mark F., Sieber, Oliver M., Liao, Yang, Mooi, Jennifer K., Vukelic, Natalia, Reehorst, Camilla M., Afshar-Sterle, Shoukat, Whitehall, Vicki L. J., Fennell, Lochlan, Abud, Helen E., Tebbutt, Niall C., Phillips, Wayne A., Williams, David S., Shi, Wei, Mielke, Lisa A., Ernst, Matthias, Dhillon, Amardeep S., Clemons, Nicholas J., and Mariadason, John M.

Published
2022
Full Text
View/download PDF

7. Abstract PR007: Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions

Author

Milne, Julia V., primary, Mustafa, Ebtihal, additional, Fujihara, Kenji, additional, Kusnadi, Eric, additional, Trigos, Anna, additional, Thio, Niko, additional, Pechlivanis, Maree, additional, Cabalag, Carlos, additional, Gulati, Twishi, additional, Simpson, Kaylene, additional, Duong, Cuong, additional, Furic, Luc, additional, Phillips, Wayne, additional, and Clemons, Nicholas, additional

Published
2024
Full Text
View/download PDF

12. Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy

Author

Al-janabi, Haider, primary, Moyes, Katy, additional, Allen, Richard J, additional, Fisher, Matthew, additional, Crespo, Mateus, additional, Gurel, Bora, additional, Rescigno, Pasquale, additional, De Bono, Johann, additional, Nunns, Harry, additional, Bailey, Christopher, additional, Juncker-Jensen, Anna, additional, Muthana, Munitta, additional, Phillips, Wayne A, additional, Pearson, Helen, additional, Taplin, Mary-Ellen, additional, Brown, Janet E, additional, and Lewis, Claire E, additional

Published
2024
Full Text
View/download PDF

14. Development of an in vivo syngeneic mouse transplant model of invasive intestinal adenocarcinoma driven by endogenous expression of Pik3caH1047R and Apc loss.

Author

de las Heras, Francesc, Mitchell, Camilla B., Murray, William K., Clemons, Nicholas J., and Phillips, Wayne A.

Abstract

Preclinical models that replicate patient tumours as closely as possible are crucial for translational cancer research. While in vitro cancer models have many advantages in assessing tumour response therapy, in vivo systems are essential to enable evaluation of the role of the tumour cell extrinsic factors, such as the tumour microenvironment and host immune system. The requirement for a functional immune system is particularly important given the current focus on immunotherapies. Therefore, we set out to generate an immunocompetent, transplantable model of colorectal cancer suitable for in vivo assessment of immune-based therapeutic approaches. Intestinal tumours from a genetically engineered mouse model, driven by expression of a Pik3ca mutation and loss of Apc, were transplanted into wild type C57BL/6 host mice and subsequently passaged to form a novel syngeneic transplant model of colorectal cancer. Our work confirms the potential to develop a panel of mouse syngeneic grafts, akin to human PDX panels, from different genetically engineered, or carcinogen-induced, mouse models. Such panels would allow the in vivo testing of new pharmaceutical and immunotherapeutic treatment approaches across a range of tumours with a variety of genetic driver mutations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. HOXA13 in etiology and oncogenic potential of Barrett’s esophagus

Author

Janmaat, Vincent T., Nesteruk, Kateryna, Spaander, Manon C. W., Verhaar, Auke P., Yu, Bingting, Silva, Rodrigo A., Phillips, Wayne A., Magierowski, Marcin, van de Winkel, Anouk, Stadler, H. Scott, Sandoval-Guzmán, Tatiana, van der Laan, Luc J. W., Kuipers, Ernst J., Smits, Ron, Bruno, Marco J., Fuhler, Gwenny M., Clemons, Nicholas J., and Peppelenbosch, Maikel P.

Published
2021
Full Text
View/download PDF

17. Molecular and genomic characterisation of a panel of human anal cancer cell lines

Author

Guerra, Glen R., Kong, Joseph C., Millen, Rosemary M., Read, Matthew, Liu, David S., Roth, Sara, Sampurno, Shienny, Sia, Joseph, Bernardi, Maria-Pia, Chittleborough, Timothy J., Behrenbruch, Corina C., Teh, Jiasian, Xu, Huiling, Haynes, Nicole M., Yu, Jiaan, Lupat, Richard, Hawkes, David, Di Costanzo, Natasha, Tothill, Richard W., Mitchell, Catherine, Ngan, Samuel Y., Heriot, Alexander G., Ramsay, Robert G., and Phillips, Wayne A.

Published
2021
Full Text
View/download PDF

18. Mutationally Activated PIK3CAH1047R Cooperates with BRAFV600E to Promote Lung Cancer Progression

Author

Trejo, Christy L, Green, Shon, Marsh, Victoria, Collisson, Eric A, Iezza, Gioia, Phillips, Wayne A, and McMahon, Martin

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Lung Cancer, Rare Diseases, Cancer, Lung, Genetics, Aetiology, 2.1 Biological and endogenous factors, Adenocarcinoma, Animals, Apoptosis, Blotting, Western, Cell Movement, Cell Proliferation, Cell Transformation, Neoplastic, Class I Phosphatidylinositol 3-Kinases, Disease Progression, Immunoenzyme Techniques, Lung Neoplasms, Mice, Mice, Knockout, Mutation, PTEN Phosphohydrolase, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins B-raf, Signal Transduction, Survival Rate, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Adenocarcinoma of the lung, a leading cause of cancer death, frequently displays mutational activation of the KRAS proto-oncogene but, unlike lung cancers expressing mutated EGFR, ROS1, or ALK, there is no pathway-targeted therapy for patients with KRAS-mutated lung cancer. In preclinical models, expression of oncogenic KRAS(G12D) in the lung epithelium of adult mice initiates development of lung adenocarcinoma through activation of downstream signaling pathways. In contrast, mutationally activated BRAF(V600E), a KRAS effector, fails to initiate lung carcinogenesis despite highly efficient induction of benign lung tumorigenesis. To test if phosphoinositide 3-kinase (PI3K)-α (PIK3CA), another KRAS effector, might cooperate with oncogenic BRAF(V600E) to promote lung cancer progression, we used mice carrying a conditional allele of Pik3ca that allows conversion of the wild-type catalytic subunit of PIK3CA to mutationally activated PIK3CA(H1047R). Although expression of PIK3CA(H1047R) in the lung epithelium, either alone or in combination with PTEN silencing, was without phenotype, concomitant expression of BRAF(V600E) and PIK3CA(H1047R) led to dramatically decreased tumor latency and increased tumor burden compared with BRAF(V600E) alone. Most notably, coexpression of BRAF(V600E) and PIK3CA(H1047R) elicited lung adenocarcinomas in a manner reminiscent of the effects of KRAS(G12D). These data emphasize a role for PI3K signaling, not in lung tumor initiation per se, but in both the rate of tumor growth and the propensity of benign lung tumors to progress to a malignant phenotype. Finally, biologic and biochemical analysis of BRAF(V600E)/PIK3CA(H1047R)-expressing mouse lung cancer cells revealed mechanistic clues about cooperative regulation of the cell-division cycle and apoptosis by these oncogenes.

Published
2013

19. A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Author

Collisson, Eric A, Trejo, Christy L, Silva, Jillian M, Gu, Shenda, Korkola, James E, Heiser, Laura M, Charles, Roch-Philippe, Rabinovich, Brian A, Hann, Byron, Dankort, David, Spellman, Paul T, Phillips, Wayne A, Gray, Joe W, and McMahon, Martin

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Biological Sciences, Rare Diseases, Pancreatic Cancer, Cancer, Genetics, Digestive Diseases, Good Health and Well Being, Animals, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Cell Transformation, Neoplastic, Extracellular Signal-Regulated MAP Kinases, Genes, ras, Humans, Immunoblotting, Immunohistochemistry, MAP Kinase Signaling System, Mice, Mitogen-Activated Protein Kinase Kinases, Pancreatic Neoplasms, Proto-Oncogene Proteins B-raf, Oncology and Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

UnlabelledKRAS mutation is a hallmark of pancreatic ductal adenocarcinoma (PDA) but remains an intractable pharmacologic target. Consequently, defining RAS effector pathway(s) required for PDA initiation and maintenance is critical to improve treatment of this disease. Here, we show that expression of BRAF(V600E), but not PIK3CA(H1047R), in the mouse pancreas leads to pancreatic intraepithelial neoplasia (PanIN) lesions. Moreover, concomitant expression of BRAF(V600E) and TP53(R270H) result in lethal PDA. We tested pharmacologic inhibitors of RAS effectors against multiple human PDA cell lines. Mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) inhibition was highly effective both in vivo and in vitro and was synergistic with AKT inhibition in most cell lines tested. We show that RAF→MEK→ERK signaling is central to the initiation and maintenance of PDA and to rational combination strategies in this disease. These results emphasize the value of leveraging multiple complementary experimental systems to prioritize pathways for effective intervention strategies in PDA.SignificancePDA is diffi cult to treat, in large part, due to recurrent mutations in the KRAS gene. Here, we defi ne rational treatment approaches for the disease achievable today with existing drug combinations by thorough genetic and pharmacologic dissection of the major KRAS effector pathways, RAF→MEK→ERK and phosphoinositide 3′-kinase (PI3'K)→AKT.

Published
2012

20. Caspase-2 protects against ferroptotic cell death

Author

Dawar, Swati, primary, Benitez, Mariana C., additional, Lim, Yoon, additional, Dite, Toby A., additional, Yousef, Jumana M., additional, Thio, Niko, additional, Garciaz, Sylvain, additional, Jackson, Thomas D., additional, Milne, Julia V., additional, Dagley, Laura F., additional, Phillips, Wayne A., additional, Kumar, Sharad, additional, and Clemons, Nicholas J., additional

Published
2023
Full Text
View/download PDF

21. Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing

Author

Chiam, Karen, Mayne, George C., Watson, David I., Woodman, Richard J., Bright, Tim F., Michael, Michael Z., Karapetis, Christos S., Irvine, Tanya, Phillips, Wayne A., Hummel, Richard, Wang, Tingting, Pimlott, Letitia K., Marri, Shashikanth, Astill, David StJ., Ruszkiewicz, Andrew R., Thompson, Sarah K., and Hussey, Damian J.

Published
2018
Full Text
View/download PDF

22. Supplemetary Material and Tables from Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth

Author

Pearson, Helen B., primary, Li, Jason, primary, Meniel, Valerie S., primary, Fennell, Christina M., primary, Waring, Paul, primary, Montgomery, Karen G., primary, Rebello, Richard J., primary, Macpherson, Arthi A., primary, Koushyar, Sarah, primary, Furic, Luc, primary, Cullinane, Carleen, primary, Clarkson, Richard W., primary, Smalley, Matthew J., primary, Simpson, Kaylene J., primary, Phesse, Toby J., primary, Shepherd, Peter R., primary, Humbert, Patrick O., primary, Sansom, Owen J., primary, and Phillips, Wayne A., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 1 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Author

Collisson, Eric A., primary, Trejo, Christy L., primary, Silva, Jillian M., primary, Gu, Shenda, primary, Korkola, James E., primary, Heiser, Laura M., primary, Charles, Roch-Philippe, primary, Rabinovich, Brian A., primary, Hann, Byron, primary, Dankort, David, primary, Spellman, Paul T., primary, Phillips, Wayne A., primary, Gray, Joe W., primary, and McMahon, Martin, primary

Published
2023
Full Text
View/download PDF

24. Data from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Author

Collisson, Eric A., primary, Trejo, Christy L., primary, Silva, Jillian M., primary, Gu, Shenda, primary, Korkola, James E., primary, Heiser, Laura M., primary, Charles, Roch-Philippe, primary, Rabinovich, Brian A., primary, Hann, Byron, primary, Dankort, David, primary, Spellman, Paul T., primary, Phillips, Wayne A., primary, Gray, Joe W., primary, and McMahon, Martin, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Information from SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status

Author

Fujihara, Kenji M., primary, Corrales Benitez, Mariana, primary, Cabalag, Carlos S., primary, Zhang, Bonnie Z., primary, Ko, Hyun S., primary, Liu, David S., primary, Simpson, Kaylene J., primary, Haupt, Ygal, primary, Lipton, Lara, primary, Haupt, Sue, primary, Phillips, Wayne A., primary, and Clemons, Nicholas J., primary

Published
2023
Full Text
View/download PDF

27. Data from Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth

Author

Pearson, Helen B., primary, Li, Jason, primary, Meniel, Valerie S., primary, Fennell, Christina M., primary, Waring, Paul, primary, Montgomery, Karen G., primary, Rebello, Richard J., primary, Macpherson, Arthi A., primary, Koushyar, Sarah, primary, Furic, Luc, primary, Cullinane, Carleen, primary, Clarkson, Richard W., primary, Smalley, Matthew J., primary, Simpson, Kaylene J., primary, Phesse, Toby J., primary, Shepherd, Peter R., primary, Humbert, Patrick O., primary, Sansom, Owen J., primary, and Phillips, Wayne A., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Dataset 1 from SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status

Author

Fujihara, Kenji M., primary, Corrales Benitez, Mariana, primary, Cabalag, Carlos S., primary, Zhang, Bonnie Z., primary, Ko, Hyun S., primary, Liu, David S., primary, Simpson, Kaylene J., primary, Haupt, Ygal, primary, Lipton, Lara, primary, Haupt, Sue, primary, Phillips, Wayne A., primary, and Clemons, Nicholas J., primary

Published
2023
Full Text
View/download PDF

29. Figure S2 from Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth

Author

Pearson, Helen B., primary, Li, Jason, primary, Meniel, Valerie S., primary, Fennell, Christina M., primary, Waring, Paul, primary, Montgomery, Karen G., primary, Rebello, Richard J., primary, Macpherson, Arthi A., primary, Koushyar, Sarah, primary, Furic, Luc, primary, Cullinane, Carleen, primary, Clarkson, Richard W., primary, Smalley, Matthew J., primary, Simpson, Kaylene J., primary, Phesse, Toby J., primary, Shepherd, Peter R., primary, Humbert, Patrick O., primary, Sansom, Owen J., primary, and Phillips, Wayne A., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table 2 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Author

Collisson, Eric A., primary, Trejo, Christy L., primary, Silva, Jillian M., primary, Gu, Shenda, primary, Korkola, James E., primary, Heiser, Laura M., primary, Charles, Roch-Philippe, primary, Rabinovich, Brian A., primary, Hann, Byron, primary, Dankort, David, primary, Spellman, Paul T., primary, Phillips, Wayne A., primary, Gray, Joe W., primary, and McMahon, Martin, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure Legends 1-5, Table Legends 1-2 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Author

Collisson, Eric A., primary, Trejo, Christy L., primary, Silva, Jillian M., primary, Gu, Shenda, primary, Korkola, James E., primary, Heiser, Laura M., primary, Charles, Roch-Philippe, primary, Rabinovich, Brian A., primary, Hann, Byron, primary, Dankort, David, primary, Spellman, Paul T., primary, Phillips, Wayne A., primary, Gray, Joe W., primary, and McMahon, Martin, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 4 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Author

Collisson, Eric A., primary, Trejo, Christy L., primary, Silva, Jillian M., primary, Gu, Shenda, primary, Korkola, James E., primary, Heiser, Laura M., primary, Charles, Roch-Philippe, primary, Rabinovich, Brian A., primary, Hann, Byron, primary, Dankort, David, primary, Spellman, Paul T., primary, Phillips, Wayne A., primary, Gray, Joe W., primary, and McMahon, Martin, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Materials and Methods from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Author

Collisson, Eric A., primary, Trejo, Christy L., primary, Silva, Jillian M., primary, Gu, Shenda, primary, Korkola, James E., primary, Heiser, Laura M., primary, Charles, Roch-Philippe, primary, Rabinovich, Brian A., primary, Hann, Byron, primary, Dankort, David, primary, Spellman, Paul T., primary, Phillips, Wayne A., primary, Gray, Joe W., primary, and McMahon, Martin, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 5 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Author

Collisson, Eric A., primary, Trejo, Christy L., primary, Silva, Jillian M., primary, Gu, Shenda, primary, Korkola, James E., primary, Heiser, Laura M., primary, Charles, Roch-Philippe, primary, Rabinovich, Brian A., primary, Hann, Byron, primary, Dankort, David, primary, Spellman, Paul T., primary, Phillips, Wayne A., primary, Gray, Joe W., primary, and McMahon, Martin, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 1 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Author

Collisson, Eric A., primary, Trejo, Christy L., primary, Silva, Jillian M., primary, Gu, Shenda, primary, Korkola, James E., primary, Heiser, Laura M., primary, Charles, Roch-Philippe, primary, Rabinovich, Brian A., primary, Hann, Byron, primary, Dankort, David, primary, Spellman, Paul T., primary, Phillips, Wayne A., primary, Gray, Joe W., primary, and McMahon, Martin, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 2 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Author

Collisson, Eric A., primary, Trejo, Christy L., primary, Silva, Jillian M., primary, Gu, Shenda, primary, Korkola, James E., primary, Heiser, Laura M., primary, Charles, Roch-Philippe, primary, Rabinovich, Brian A., primary, Hann, Byron, primary, Dankort, David, primary, Spellman, Paul T., primary, Phillips, Wayne A., primary, Gray, Joe W., primary, and McMahon, Martin, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 3 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Author

Collisson, Eric A., primary, Trejo, Christy L., primary, Silva, Jillian M., primary, Gu, Shenda, primary, Korkola, James E., primary, Heiser, Laura M., primary, Charles, Roch-Philippe, primary, Rabinovich, Brian A., primary, Hann, Byron, primary, Dankort, David, primary, Spellman, Paul T., primary, Phillips, Wayne A., primary, Gray, Joe W., primary, and McMahon, Martin, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Tables and Figures from Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Author

Teo, Zhi Ling, primary, Versaci, Stephanie, primary, Dushyanthen, Sathana, primary, Caramia, Franco, primary, Savas, Peter, primary, Mintoff, Chris P., primary, Zethoven, Magnus, primary, Virassamy, Balaji, primary, Luen, Stephen J., primary, McArthur, Grant A., primary, Phillips, Wayne A., primary, Darcy, Phillip K., primary, and Loi, Sherene, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Methods from Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Author

Teo, Zhi Ling, primary, Versaci, Stephanie, primary, Dushyanthen, Sathana, primary, Caramia, Franco, primary, Savas, Peter, primary, Mintoff, Chris P., primary, Zethoven, Magnus, primary, Virassamy, Balaji, primary, Luen, Stephen J., primary, McArthur, Grant A., primary, Phillips, Wayne A., primary, Darcy, Phillip K., primary, and Loi, Sherene, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table S1 from Pretreatment Transcriptional Profiling for Predicting Response to Neoadjuvant Chemoradiotherapy in Rectal Adenocarcinoma

Author

Brettingham-Moore, Kate H., primary, Duong, Cuong P., primary, Greenawalt, Danielle M., primary, Heriot, Alexander G., primary, Ellul, Jason, primary, Dow, Christopher A., primary, Murray, William K., primary, Hicks, Rodney J., primary, Tjandra, Joe, primary, Chao, Michael, primary, Bui, Andrew, primary, Joon, Daryl Lim, primary, Thomas, Robert J. S., primary, and Phillips, Wayne A., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results